Marina Biotech Achieves Broad Patent Coverage for DiLA2 Nucleic Acid Delivery Technology in U.S., Europe and Japan
23. Januar 2014 07:30 ET
|
Marina Biotech, Inc.
BOSTON, MA--(Marketwired - Jan 23, 2014) - Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading oligonucleotide-based drug discovery and development company, announced today that a decision to grant a...
Marina Biotech Strengthens the Intellectual Property Estate for the Transkingdom RNA Interference Nucleic Acid Delivery Technology
14. Januar 2014 07:30 ET
|
Marina Biotech, Inc.
BOSTON, MA--(Marketwired - Jan 14, 2014) - Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading oligonucleotide-based drug discovery and development company, announced today that the Canadian...
Marina Biotech Strengthens the Intellectual Property Estate for SMARTICLES(R) Nucleic Acid Delivery Technology
09. Januar 2014 07:30 ET
|
Marina Biotech, Inc.
BOSTON, MA--(Marketwired - Jan 9, 2014) - Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading oligonucleotide-based drug discovery and development company, announced today the grant and issuance of...
Marina Biotech Announces Organizational Changes
03. Januar 2014 07:30 ET
|
Marina Biotech, Inc.
BOSTON, MA--(Marketwired - Jan 3, 2014) - Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading oligonucleotide-based drug discovery and development company, announced today that Philip C. Ranker will...
Marina Biotech and Mirna Therapeutics Amend License Agreement for the Development of microRNA-Based Therapeutics
02. Januar 2014 07:30 ET
|
Marina Biotech, Inc.
BOSTON, MA and AUSTIN, TX--(Marketwired - Jan 2, 2014) - Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading oligonucleotide-based drug discovery and development company, and Mirna Therapeutics,...
Marina Biotech Monetizes UNA Intellectual Property Estate Through Agreement With Arcturus Therapeutics
14. August 2013 07:00 ET
|
Marina Biotech, Inc.
CAMBRIDGE, MA--(Marketwired - Aug 14, 2013) - Marina Biotech, Inc. (PINKSHEETS: MRNA)
Assigns Unlocked Nucleobase Analog (UNA) patents to Arcturus but retains...
Marina Biotech Announces That Licensee Mirna Therapeutics Reported Initiation of a Phase 1 Clinical Trial of Anticancer Drug MRX34
13. Mai 2013 08:00 ET
|
Marina Biotech, Inc.
BOTHELL, WA--(Marketwired - May 13, 2013) - Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and development company, today announced that the...
Marina Biotech, Inc. Announces Year-to-Date 2012 Financial Results
06. Dezember 2012 06:30 ET
|
Marina Biotech, Inc.
BOTHELL, WA--(Marketwire - Dec 6, 2012) - Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading RNAi-based drug discovery and development company, yesterday reported financial results for the...
Marina Biotech Announces That Licensee ProNAi Therapeutics Reported Phase 1 Study Results Using SMARTICLES(R) Nucleic Acid Delivery Technology
05. Dezember 2012 06:30 ET
|
Marina Biotech, Inc.
BOTHELL, WA--(Marketwire - Dec 5, 2012) - Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and development company, today announced that the Company's licensee,...
Marina Biotech Receives Key Patent Issuance From the USPTO for Its Unlocked Nucleobase Analog (UNA) Chemistry
04. Dezember 2012 06:30 ET
|
Marina Biotech, Inc.
BOTHELL, WA--(Marketwire - Dec 4, 2012) - Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and development company, today announced that the U.S. Patent and...